Asian Pacific Journal of Cancer Prevention

  • 제13권4호
  • /
  • Pages.1209-1215
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Hypersensitivity Reactions to Oxaliplatin: Clinical Features and Risk Factors in Koreans

  • Kim, Mi-Yeong (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kang, Sung-Yoon (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Lee, Suh-Young (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Yang, Min-Suk (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kim, Min-Hye (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Song, Woo-Jung (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kim, Sae-Hoon (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kim, Yo-Jung (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Lee, Keun-Wook (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Cho, Sang-Heon (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Min, Kyung-Up (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Lee, Jong-Seok (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kim, Jee-Hyun (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Chang, Yoon-Seok (Department of Internal Medicine, Seoul National University College of Medicine)
  • 발행 : 2012.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background and Aim: Oxaliplatin hypersensitivity is a well-known adverse reaction but the prevalence varies and data for frequency and clinical features have not been reported for Korea. Here we evaluates the prevalence and risk factors for hypersensitivity reactions to oxaliplatin after chemotherapy. Methods: Clinical information on all patients treated with oxaliplatin was retrospectively reviewed in electronic medical records between August 2009 and July 2010 in Seoul National University Bundang Hospital. Patients who experienced hypersensitivity reactions to oxaliplatin were compared with those who did not. Results: A total of 393 patients received oxaliplatin, with 42 (10.7%) experiencing hypersensitivity reactions including three cases of anaphylaxis. Median cycle of the first hypersensitivity reaction was 8. Reactions correlated with lower dexamethasone doses. Other variables were not significant. Conclusions: The prevalence of hypersensitivity reactions was 10.7%, symptoms being mostly mild and cutaneous. Lower dexamethasone doses could be a predictor for hypersensitivity reactions to oxaliplatin.

키워드

참고문헌

  1. Andre T, Boni C, Mounedji-Boudiaf L, et al (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 350, 2343-51. https://doi.org/10.1056/NEJMoa032709
  2. Bajetta E, Pietrantonio F, Di Bartolomeo M, Buzzoni R (2010). Acute immune-mediated thrombocytopenia due to oxaliplatin administration: a case report. Tumori, 96, 154-6.
  3. Basu R, Rajkumar A, Datta NR (2002). Anaphylaxis to cisplatin following nine previous uncomplicated cycles. Int J Clin Oncol, 7, 365-7. https://doi.org/10.1007/s101470200056
  4. Bautista MA, Stevens WT, Chen CS, et al (2010). Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol, 3, 12. https://doi.org/10.1186/1756-8722-3-12
  5. Bhargava P, Gammon D, McCormick MJ (2004). Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer, 100, 211-2. https://doi.org/10.1002/cncr.11901
  6. Brandi G, Pantaleo MA, Galli C, et al (2003). Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer, 89, 477-81. https://doi.org/10.1038/sj.bjc.6601155
  7. Collet E, Leguy-Seguin V, Jolimoy G, et al (2007). Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immun, 119, 726-30. https://doi.org/10.1016/j.jaci.2006.11.640
  8. Faivre S, Chan C, Salinas R, et al (2003). DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol, 66, 225-37. https://doi.org/10.1016/S0006-2952(03)00260-0
  9. Garufi C, Cristaudo A, Vanni B, et al (2003). Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol, 14, 497-8. https://doi.org/10.1093/annonc/mdg092
  10. Gowda A, Goel R, Berdzik J, et al (2004). Hypersensitivity Reactions to oxaliplatin: incidence and management. Oncology, 18, 1671-5; discussion 6, 80, 83-4.
  11. Ichikawa Y, Goto A, Hirokawa S, et al (2009). Allergic reactions to oxaliplatin in a single institute in Japan. Jpn J Clin Oncol, 39, 616-20. https://doi.org/10.1093/jjco/hyp070
  12. Kelland L (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer, 7, 573-84. https://doi.org/10.1038/nrc2167
  13. Kidera Y, Satoh T, Ueda S, et al (2011). High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol, 16, 244-9. https://doi.org/10.1007/s10147-010-0170-6
  14. Kim BH, Bradley T, Tai J, Budman DR (2009). Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology, 76, 231-8. https://doi.org/10.1159/000205263
  15. Koren C, Yerushalmi R, Katz A, et al (2002). Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol, 25, 625-6. https://doi.org/10.1097/00000421-200212000-00020
  16. Lee KH, Park YJ, Kim ES, et al (2006). Hypersensitivity reactions to oxaliplatin. Cancer Res Treat, 38, 240-1. https://doi.org/10.4143/crt.2006.38.4.240
  17. Lee MY, Yang MH, Liu JH, et al (2007). Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer, 15, 89-93. https://doi.org/10.1007/s00520-006-0107-9
  18. Lim KH, Huang MJ, Lin HC, et al. (2004). Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. Anticancer Drugs, 15, 605-7. https://doi.org/10.1097/01.cad.0000132235.38297.7c
  19. Maindrault-Goebel F, Andre T, Tournigand C, et al. (2005). Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer, 41, 2262-7. https://doi.org/10.1016/j.ejca.2005.06.021
  20. Makrilia N, Syrigou E, Kaklamanos I, et al (2010). Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs, ??, ??.
  21. Markman M, Kennedy A, Webster K, et al (1999). An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol, 125, 427-9. https://doi.org/10.1007/s004320050297
  22. Mason JM, Rees G (2010). Oxaliplatin-induced acute thrombocytopenia. J Oncol Pharm Pract, 17, 433-5.
  23. Morgan JS, Adams M, Mason MD (1994). Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer, 30A, 1205-6.
  24. Petit-Laurent F, Conroy T, Krakowski I, et al (2000). [Delayed urticaria with oxaliplatin]. Gastroenterol Clin Biol, 24, 851-2.
  25. Polyzos A, Tsavaris N, Gogas H, et al (2009). Clinical features of hypersensitivity reactions to oxaliplatin: a 10- year experience. Oncology, 76, 36-41. https://doi.org/10.1159/000178163
  26. Polyzos A, Tsavaris N, Kosmas C, et al (2001). Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology, 61, 129-33. https://doi.org/10.1159/000055363
  27. Santini D, Tonini G, Salerno A, et al (2001). Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol, 12, 132-3. https://doi.org/10.1023/A:1008366223918
  28. Shao YY, Hu FC, Liang JT, et al. (2010). Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions. J Formos Med Assoc, 109, 362-8. https://doi.org/10.1016/S0929-6646(10)60064-2
  29. Shibata Y, Ariyama H, Baba E, et al (2009). Oxaliplatininduced allergic reaction in patients with colorectal cancer in Japan. Int J Clin Oncol, 14, 397-401. https://doi.org/10.1007/s10147-009-0883-6
  30. Siu SW, Chan RT, Au GK (2006). Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol, 17, 259-61. https://doi.org/10.1093/annonc/mdl270
  31. Thomas RR, Quinn MG, Schuler B, Grem JL (2003). Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer, 97, 2301-7. https://doi.org/10.1002/cncr.11379
  32. Trotti A, Colevas AD, Setser A, et al (2003). CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 13, 176-81. https://doi.org/10.1016/S1053-4296(03)00031-6
  33. Villee C, Tennstedt D, Marot L, et al (2010). Delayed urticaria with oxaliplatin. Contact Dermatitis, 63, 50-3. https://doi.org/10.1111/j.1600-0536.2010.01738.x
  34. Zanotti KM, Rybicki LA, Kennedy AW, et al (2001). Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol, 19, 3126-9.

피인용 문헌

  1. Updates on desensitization for hypersensitivity reactions related to chemotherapy vol.1, pp.4, 2013, https://doi.org/10.4168/aard.2013.1.4.295
  2. Hypersensitivity reactions associated with oxaliplatin and their clinical management vol.13, pp.11, 2014, https://doi.org/10.1517/14740338.2014.963551
  3. Oxaliplatin vol.1483, pp.1, 2014, https://doi.org/10.1007/s40278-014-8122-y
  4. Transcriptional factor snail controls tumor neovascularization, growth and metastasis in mouse model of human ovarian carcinoma vol.3, pp.1, 2014, https://doi.org/10.1186/s40169-014-0028-z